-
Je něco špatně v tomto záznamu ?
Evaluation of Serum Cytokeratines, Thymidine Kinase, and Growth Factors as Cancer Biomarkers in Colorectal Cancer
M. Karlíková, M. Čurillová, L. Pecen, V. Karnos, V. Karnos, O. Topolčan
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
- MeSH
- antigen CA-19-9 * krev MeSH
- antigeny nádorové krev MeSH
- dospělí MeSH
- insulinu podobný růstový faktor I metabolismus MeSH
- karcinoembryonální antigen * krev MeSH
- keratin-19 krev MeSH
- keratiny krev MeSH
- kolorektální nádory * krev diagnóza patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery * krev MeSH
- peptidy MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- ROC křivka MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- thymidinkináza * krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND/AIM: Classical serum cancer biomarkers, such as carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9), remain important tools in colorectal cancer (CRC) management for disease follow up. However, their sensitivity and specificity are low for diagnostic and prognostic evaluation. The aim of this study was to evaluate the potential of biomarkers reflecting biological activity of tumors - tissue polypeptide specific antigen (TPS), cytokeratin fragment 19 (CYFRA 21-1), thymidine kinase (TK), insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGF-BP3) - together with the CEA and CA 19-9 in CRC diagnosis and prognosis. PATIENTS AND METHODS: This is a retrospective study including 148 CRC patients and 68 age-matched healthy subjects. Serum biomarkers were measured in pre-operative serum samples using immunoanalytical methods. The end-point for the diagnostic evaluation was the area under the receiving operating characteristic curve (AUC ROC) of the biomarkers. The end-point for the prognostic evaluation was overall survival. RESULTS: Serum levels of CEA, CA 19-9, TPS, and TK were significantly increased in CRC early-stage patients compared with healthy controls. Each of the studied biomarkers had AUC between 0.6 and 0.7. Analysis of survival demonstrated that the patients with CEA, CA 19-9, cytokeratin, and TK above optimal cut offs had significantly shorter survival. A multivariate analysis performed on all the study biomarkers resulted in the selection of CYFRA 21-1 as the best performing biomarker with hazard ratio 10.413. CONCLUSION: The combination of cytokeratins and thymidine kinase with classical cancer biomarkers enables the prediction of tumor aggressiveness and long-term prognosis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013337
- 003
- CZ-PrNML
- 005
- 20240905133317.0
- 007
- ta
- 008
- 240725s2024 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/anticanres.17124 $2 doi
- 035 __
- $a (PubMed)38925804
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Karlíková, Marie $u Division of Immunochemical Diagnostics, University Hospital Pilsen and Charles University, Medical Faculty in Pilsen, Pilsen, Czech Republic; karlikovam@fnplzen.cz
- 245 10
- $a Evaluation of Serum Cytokeratines, Thymidine Kinase, and Growth Factors as Cancer Biomarkers in Colorectal Cancer / $c M. Karlíková, M. Čurillová, L. Pecen, V. Karnos, V. Karnos, O. Topolčan
- 520 9_
- $a BACKGROUND/AIM: Classical serum cancer biomarkers, such as carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9), remain important tools in colorectal cancer (CRC) management for disease follow up. However, their sensitivity and specificity are low for diagnostic and prognostic evaluation. The aim of this study was to evaluate the potential of biomarkers reflecting biological activity of tumors - tissue polypeptide specific antigen (TPS), cytokeratin fragment 19 (CYFRA 21-1), thymidine kinase (TK), insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGF-BP3) - together with the CEA and CA 19-9 in CRC diagnosis and prognosis. PATIENTS AND METHODS: This is a retrospective study including 148 CRC patients and 68 age-matched healthy subjects. Serum biomarkers were measured in pre-operative serum samples using immunoanalytical methods. The end-point for the diagnostic evaluation was the area under the receiving operating characteristic curve (AUC ROC) of the biomarkers. The end-point for the prognostic evaluation was overall survival. RESULTS: Serum levels of CEA, CA 19-9, TPS, and TK were significantly increased in CRC early-stage patients compared with healthy controls. Each of the studied biomarkers had AUC between 0.6 and 0.7. Analysis of survival demonstrated that the patients with CEA, CA 19-9, cytokeratin, and TK above optimal cut offs had significantly shorter survival. A multivariate analysis performed on all the study biomarkers resulted in the selection of CYFRA 21-1 as the best performing biomarker with hazard ratio 10.413. CONCLUSION: The combination of cytokeratins and thymidine kinase with classical cancer biomarkers enables the prediction of tumor aggressiveness and long-term prognosis.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a thymidinkináza $x krev $7 D013937
- 650 12
- $a kolorektální nádory $x krev $x diagnóza $x patologie $7 D015179
- 650 12
- $a nádorové biomarkery $x krev $7 D014408
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a karcinoembryonální antigen $x krev $7 D002272
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a antigen CA-19-9 $x krev $7 D018395
- 650 _2
- $a ROC křivka $7 D012372
- 650 _2
- $a insulinu podobný růstový faktor I $x metabolismus $7 D007334
- 650 _2
- $a keratiny $x krev $7 D007633
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a keratin-19 $x krev $7 D053539
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a antigeny nádorové $x krev $7 D000951
- 650 _2
- $a peptidy $7 D010455
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Čurillová, Magda $u Department of Surgery, University Hospital Pilsen and Charles University, Medical Faculty in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Pecen, Ladislav $u Division of Immunochemical Diagnostics, University Hospital Pilsen and Charles University, Medical Faculty in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Karnos, Václav $u Department of Surgery, University Hospital Pilsen and Charles University, Medical Faculty in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Karnos, Václav $u Department of Surgery, University Hospital Pilsen and Charles University, Medical Faculty in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Topolčan, Ondřej $u Division of Immunochemical Diagnostics, University Hospital Pilsen and Charles University, Medical Faculty in Pilsen, Pilsen, Czech Republic
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 44, č. 7 (2024), s. 3105-3113
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38925804 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133311 $b ABA008
- 999 __
- $a ok $b bmc $g 2143259 $s 1225203
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 44 $c 7 $d 3105-3113 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20240725
